Stocks
Funds
Screener
Sectors
Watchlists
SQL

SQL - SeqLL Inc. Stock Price, Fair Value and News

$5.71 
Delayed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

SQL Price Action

Last 7 days

-13.3%


Last 90 days

4.4%


Trailing 12 Months

-62.2%

SQL RSI Chart

SQL Valuation

Market Cap

287.8M

Price/Earnings (Trailing)

-4.6

Price/Sales (Trailing)

0.72

EV/EBITDA

-3.17

Price/Free Cashflow

-43.35

SQL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SQL Fundamentals

SQL Revenue

Revenue (TTM)

399.6M

Rev. Growth (Yr)

10.25%

Rev. Growth (Qtr)

3.03%

SQL Earnings

Earnings (TTM)

-62.6M

Earnings Growth (Yr)

-79.79%

Earnings Growth (Qtr)

87.16%

SQL Profitability

EBT Margin

-22.73%

Return on Equity

-385.78%

Return on Assets

-46.15%

Free Cashflow Yield

-2.31%

SQL Investor Care

Shares Dilution (1Y)

97.24%

Diluted EPS (TTM)

-17.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202400399.6M0
20230000
2022189.0K000
2021289.0K248.6K208.1K167.6K
2020000329.5K
SQL
SeqLL Inc. operates as a life sciences instrumentation and research services company worldwide. It focus on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provide solutions for various applications, such as biomarker discovery and diagnostic assay developments including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and research collaboration with True Bearing Diagnostics, Inc. performing tSMS on whole-blood RNA to identify transcripts associated with coronary artery disease. Further, it has collaboration agreement with The Bernstein Laboratory to address fundamental questions in chromatin biology and epigenetic regulation; The Ting Laboratory; The Jackson Laboratory for Genomic Medicine assisting in the development of new methods for chromatin interaction analysis in single nuclei, with single-molecule resolution; Weizmann Institute of Science for developed and applied innovative single-molecule technologies; and Tetracore, Inc. to provide with tSMS systems and onsite support. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
 CEO
 WEBSITEhttps://seqll.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES7

SeqLL Inc. Frequently Asked Questions


What is the ticker symbol for SeqLL Inc.? What does SQL stand for in stocks?

SQL is the stock ticker symbol of SeqLL Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SeqLL Inc. (SQL)?

As of Thu Oct 31 2024, market cap of SeqLL Inc. is 287.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SQL stock?

You can check SQL's fair value in chart for subscribers.

Is SeqLL Inc. a good stock to buy?

The fair value guage provides a quick view whether SQL is over valued or under valued. Whether SeqLL Inc. is cheap or expensive depends on the assumptions which impact SeqLL Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SQL.

What is SeqLL Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, SQL's PE ratio (Price to Earnings) is -4.6 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SQL PE ratio will change depending on the future growth rate expectations of investors.